Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia

Conditions

Topic: Cardiovascular

Giblett JP, Axell RG, White PA, Clarke SJ, McCormick L, Read PA, Reinhold J, Brown AJ, O'Sullivan M, West NE, Dutka DP, Hoole SP.

2016-07-1914 citations

10.1186/s12933-016-0416-3

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

Liam McCormick, Patrick M. Heck, Liam Ring, A. Kydd, Sophie Clarke et al. (7 authors)

Cardiovascular Diabetology2015-08-0726 citations

10.1186/s12933-015-0259-3

Interventions

In the active DSE, patients will receive an infusion of GLP-1 intravenously at 1.2 pmol/kg/min starting 30 minutes prior to the DSE and continuing for 30 minutes into recovery. In the control scan the

Eligibility

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Global LV function at peak stress	—

Secondary

Measure	Time frame
1. Global LV function at 30 minutes recovery 2. Regional wall LV function at 30 minutes recovery 3. Regional wall LV function at peak stress	—

Countries

United Kingdom

Outcome results

None listed